Hans Schikan is a co-founder of Pharvaris. He is former CEO of Prosensa, a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases including Duchenne muscular dystrophy. Prosensa was listed on NASDAQ in 2013 and acquired by BioMarin in 2015 for up to USD 840 M.
Hans was previously at Genzyme, latest as VP for Global Marketing and Strategic Development of Genzyme’s product portfolio for rare genetic diseases. He is currently Chairman of the Board of Complix and InteRNA; Board Member of Sobi, Therachon, and Vicore Pharma.
He is Chairman a.i. of the Top Team of the Dutch Top Sector Life Sciences & Health and served on the board of Wilson Therapeutics which was aquired by Alexion in 2018 for USD 855 M. He holds a PharmD from Utrecht University.